Unnamed: 0,title,date,stock,sentiment
941614.0,Nymox Pharmaceutical Corp Files For Mixed Shelf Offering Of Up To $12M,2020-04-03 13:54:00-04:00,NYMX,neutral
941615.0,Nymox Pharma Highlights New Peer Review Publication Of Its Prostate Cancer Candidate Fexapotide In World Journal Of Urology,2020-02-24 09:31:00-05:00,NYMX,negative
941616.0,100 Biggest Movers From Yesterday,2020-02-07 04:30:00-05:00,NYMX,neutral
941617.0,74 Stocks Moving In Thursday's Mid-Day Session,2020-02-06 12:38:00-05:00,NYMX,neutral
941618.0,Stocks That Hit 52-Week Highs On Friday,2020-01-31 10:23:00-05:00,NYMX,neutral
941619.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,NYMX,negative
941620.0,70 Biggest Movers From Yesterday,2020-01-31 05:24:00-05:00,NYMX,neutral
941621.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-30 10:25:00-05:00,NYMX,neutral
941622.0,"Nymox Pharma Offers Corporate, Milestone Update",2020-01-28 09:32:00-05:00,NYMX,neutral
941623.0,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering",2020-01-07 07:57:00-05:00,NYMX,negative
941624.0,Nymox Highlights New Peer Review Article On Fexapotide Pharmaco-Ablation Experimental Studies Published In Research And Reports In Urology,2020-01-06 11:02:00-05:00,NYMX,neutral
941625.0,24 Stocks Moving in Monday's Pre-Market Session,2020-01-06 07:32:00-05:00,NYMX,neutral
941626.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,NYMX,neutral
941627.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,NYMX,neutral
941628.0,60 Biggest Movers From Yesterday,2019-12-27 04:44:00-05:00,NYMX,neutral
941629.0,"Nymox Reports Received Several New Added US, European Patents",2019-10-21 09:31:00-04:00,NYMX,neutral
941630.0,"Nymox Pharmaceutical Granted European Patent Number Ep3432907 Titled ""Neural Thread Peptide For Preventing Or Reducing The Progression Of Prostate Cancer",2019-10-16 13:36:00-04:00,NYMX,negative
941631.0,Nymox Releases End Of Q2 Investor PResentation On Website,2019-06-25 11:50:00-04:00,NYMX,neutral
941632.0,"Nymox Director Robinson Buys 11,000 @ Avg Price: $1.55",2019-06-06 11:20:00-04:00,NYMX,neutral
941633.0,"Nu,ox Pharmaceutical Director James Robinson Buys 7,500 @ Avg Price: $1.55",2019-05-28 12:16:00-04:00,NYMX,neutral
941634.0,"Nymox Pharmaceutical Has Held Its Pre-New Drug Application Chemistry Manufacturing And Controls Meeting With FDA Regarding Its Lead Product Candidate Fexapotide Triflutate, A Novel Prostate Injectable Developed For The Treatment Of Enlarged Prostate",2019-04-16 12:48:00-04:00,NYMX,positive
941635.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-01-22 12:21:00-05:00,NYMX,neutral
941636.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,NYMX,positive
941637.0,"Nymox Pharmaceutical Corp Director Robinson Buys 6,000 @ Avg Price: $1.78",2018-11-21 11:00:00-05:00,NYMX,neutral
941638.0,"Nymox Pharmaceutical Director Robinson Buys 10,000 @ Avg Price: $1.62",2018-10-26 11:50:00-04:00,NYMX,neutral
941639.0,"Nymox Pharmaceutical Director Robinson Buys 8,000 @ Avg Price: $1.67",2018-10-25 15:13:00-04:00,NYMX,neutral
941640.0,Nymox Pharmaceutical Option Alert: Jan 18 $3 Puts at the Bid: 749 @ $1.601 vs 3480 OI; Earnings 11/5 After Close [est] Ref=$1.72,2018-10-18 09:31:00-04:00,NYMX,positive
941641.0,44 Biggest Movers From Yesterday,2018-10-15 05:06:00-04:00,NYMX,neutral
941642.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,NYMX,negative
941643.0,Nymox Pharmaceutical Corporation Says Preparatory Work For Regulatory Filings 'On Track',2018-10-11 10:46:00-04:00,NYMX,neutral
941644.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,NYMX,negative
941645.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,NYMX,positive
941646.0,Nymox Reports 78 Month Results From Biopsy And Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study Of Fexapotide Triflutate: Gleason Grade Progression Reduced By 81% Overall,2018-10-09 10:03:00-04:00,NYMX,negative
941647.0,"Stocks Which Set New 52-Week Low Yesterday, October 3rd",2018-10-04 12:38:00-04:00,NYMX,negative
941648.0,"Stocks Which Set New 52-Week Low Yesterday, October 2nd",2018-10-03 13:01:00-04:00,NYMX,negative
941649.0,"Nymox Reports 'no identifiable risks or serious side effects or adverse events identified associated or linked with' Fexapotide Treatments For Prostate Cancer, Benign Prostatic Hyperplasia",2018-10-03 11:48:00-04:00,NYMX,negative
941650.0,"Stocks Which Set New 52-Week Low Yesterday, October 1st",2018-10-02 09:24:00-04:00,NYMX,negative
941651.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,NYMX,negative
941652.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,NYMX,negative
941653.0,60 Biggest Movers From Yesterday,2018-08-16 04:56:00-04:00,NYMX,neutral
941654.0,55 Stocks Moving In Wednesday's Mid-Day Session,2018-08-15 12:40:00-04:00,NYMX,neutral
941655.0,"Nymox Pharmaceutical Q2 EPS $(0.04) vs $(0.05) In Same Qtr. Last Year, Sales $88.411K vs $9.432K YoY",2018-08-13 17:19:00-04:00,NYMX,neutral
941656.0,44 Biggest Movers From Yesterday,2018-07-03 05:54:00-04:00,NYMX,neutral
941657.0,"'$NYMX PR headline: ""NYMOX Announces Expanded Marketing Plans"" But then you read down to 4th paragraph where it says the EMA submission has been withdrawn. Oh…' - STAT News' Adam F Tweets",2018-07-02 09:48:00-04:00,NYMX,neutral
941658.0,Nymox Pharmaceutical Announces Expanded European Marketing Plans For Fexapotide Triflutate,2018-07-02 09:32:00-04:00,NYMX,neutral
941659.0,44 Biggest Movers From Yesterday,2018-06-26 04:50:00-04:00,NYMX,neutral
941660.0,36 Stocks Moving In Monday's Mid-Day Session,2018-06-25 12:26:00-04:00,NYMX,neutral
941661.0,50 Biggest Movers From Friday,2018-06-25 05:46:00-04:00,NYMX,neutral
941662.0,"Nymox Pharma Reports Initiation Of Process To Relocate Co. HQ From Nassau, Bahamas To Zug, Switzerland",2018-05-07 09:05:00-04:00,NYMX,neutral
941663.0,Nymox Announces $16.25M Equity Financing With Qualified Long-Term Investors; Lead Investor Will Receive 2.5M Warrants At $8/Share For Their $12M Investment,2018-04-12 09:47:00-04:00,NYMX,neutral
941664.0,38 Biggest Movers From Yesterday,2018-03-28 05:19:00-04:00,NYMX,neutral
941665.0,"Nymox Pharm Robinson James George (Director) Buys 8,000 @ Avg Price: $3.58 (Form4)",2018-03-16 10:51:00-04:00,NYMX,neutral
941666.0,"Nymox Pharmaceutical Corp: Robinson James George (Director) Buys 8,000 @ Avg Price: $3.48 (Form4)",2018-03-12 14:10:00-04:00,NYMX,neutral
941667.0,"Nymox Pharma Director Robinson Buys 7,000 @ Avg Price: $3.18 -Form4",2018-02-12 11:02:00-05:00,NYMX,neutral
941668.0,Nymox Announces It Will Submit A NDA For Fexapotide for BPH  Later This Year,2018-02-05 11:15:00-05:00,NYMX,neutral
941669.0,Nymox Pharma Reports Results Of Phase 3 Studies Of Fexapotide Triflutate Over '09-'16 Now Published In WJU,2018-01-30 09:32:00-05:00,NYMX,neutral
941670.0,"Nymox Pharmaceutical Director James George Robinson Buys 3,000 @ Avg Price: $3.14 -Form4",2018-01-22 15:23:00-05:00,NYMX,neutral
941671.0,UPDATE: Nymox Pharma Says '81.3% Reduction in Incidence of Primary Pattern Gleason Grade Increase Compared to Control Group',2018-01-22 11:32:00-05:00,NYMX,positive
941672.0,Nymox Pharma Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study Of Fexapotide Triflutate In 146 US Men: 'Single-Treatment Leads to Long-Term 80% Reduction in Surgery and Radiotherapy...',2018-01-22 11:31:00-05:00,NYMX,negative
941673.0,"Nymox Option Alert: Jan, 2019 $3 Puts Sweep (6) at the Ask: 1000 @ $0.951 vs 1167 OI; Ref=$3.4164",2018-01-04 11:39:00-05:00,NYMX,positive
941674.0,NYMOX Shares Slightly Volatile Here As Co. Issues Release Highlighting Symposium Held On Fexapotid Trifultate Studies At AUA,2017-11-16 11:11:00-05:00,NYMX,positive
941675.0,"Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana",2017-11-07 11:17:00-05:00,NYMX,neutral
941676.0,"Nymox Pharma 6-K Shows EPS $(0.09) vs $(0.07) In Same Qtr. Last Year, Sales $30.878M vs $51.98M YoY",2017-11-06 17:11:00-05:00,NYMX,neutral
941677.0,Nymox Option Alert: Dec 15 $4 Puts Sweep (2) at the Ask: 500 @ $0.7 vs 0 OI; Ref=$3.52,2017-11-01 09:57:00-04:00,NYMX,positive
941678.0,Nymox Shares Spike To High Of $3.85 As Co. Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6,2017-10-26 12:16:00-04:00,NYMX,positive
941679.0,"Nymox Shares Spiking Higher, Up 2.96% Following PR Highlighting Panel Discussion With Abstract On Fexapotide At   American Urological Association Northeast Sectional Annual Meeting in Savannah",2017-10-13 09:39:00-04:00,NYMX,positive
941680.0,Nymox Application Validated in EU,2017-09-14 12:41:00-04:00,NYMX,positive
941681.0,Nymox Pharma Announces Its MAA Application With European Member States Has Been Validated For Fexapotide Triflutate,2017-09-14 12:41:00-04:00,NYMX,positive
941682.0,Nymox Reports Private Placements of $3 Million,2017-08-09 10:30:00-04:00,NYMX,neutral
941683.0,22 Stocks Moving In Friday's Pre-Market Session,2017-06-30 08:26:00-04:00,NYMX,neutral
941684.0,"Nymox Pharmaceutical Director James George Robinson  Buys 15,000 @ Avg Price: $3.77 -Form4",2017-06-21 16:52:00-04:00,NYMX,neutral
941685.0,"Form 4 Filing from Nymx Pharma by George James Robinson Shows Purchase of 54,500 Shares Over Numerous Transactions",2017-05-31 13:34:00-04:00,NYMX,positive
941686.0,Nymox Pharmaceutical Reports Statistically Significant Clinical Trial Results Showing Fexapotide Triflutate Improvements In First-Line Patients,2017-05-31 10:01:00-04:00,NYMX,positive
941687.0,"Nymox Pharma Q1 EPS $(0.06) vs $(0.08) YoY, Sales $78.39K vs $41.50K YoY",2017-05-16 06:11:00-04:00,NYMX,neutral
941688.0,"Nymox Shares Spike Higher, Turn Positive, Now Up 1.7%; BZ NOTE: News of Filing for Approval Was Disclosed Last Week, Press Release Wednesday Was Strictly to Highlight Conference Call",2017-05-10 11:18:00-04:00,NYMX,positive
941689.0,Nymox Pharma Shares Spike $0.30 as Co. Issues Press Release Highlighting Conference Call on May 10 at 4:30 p.m. EDT to Discuss Filing for Approval of Prostate Drug in Europe,2017-05-10 11:17:00-04:00,NYMX,positive
941690.0,NYMOX Issues Release Highlighting Filing for Marketing Approval for Fexapotide Triflutate in Europe,2017-05-03 09:31:00-04:00,NYMX,positive
941691.0,Benzinga's Option Alert Recap From April 26,2017-04-26 16:54:00-04:00,NYMX,positive
941692.0,Option Alert: Nymox May 5.0 Calls: 710 @  ASK  $0.50: 730 traded vs 3662 OI:  Earnings 5/16 Unspecified [est]  $4.93 Ref,2017-04-26 10:08:00-04:00,NYMX,positive
941693.0,Benzinga's Option Alert Recap From April 3,2017-04-03 16:27:00-04:00,NYMX,positive
941694.0,Option Alert: Nymox Apr 4.0 Calls: 750 @  ASK  $0.20: 750 traded vs 563 OI:  Earnings today After Close (est)  $3.67 Ref,2017-04-03 14:02:00-04:00,NYMX,positive
941695.0,Nymox Pops to High of $3.84 on Volume,2017-04-03 14:01:00-04:00,NYMX,neutral
941696.0,Watch These 5 Huge Put Purchases In Thursday Trade,2017-03-30 04:15:00-04:00,NYMX,positive
941697.0,Option Alert: Nymox Apr 3.0 Puts: 500 @  ASK  $0.15: 503 traded vs 1051 OI:  Earnings tmrrw After Close (est)  $3.72 Ref,2017-03-29 11:11:00-04:00,NYMX,positive
941698.0,Nymox Pharma Says Sees Submitting Initial Filing Seeking Approval for Fexapotide Triflutate in Next Few Weeks,2017-03-29 10:46:00-04:00,NYMX,positive
941700.0,Option Alert: Nymox Feb 2.5 Puts: 500 @  ASK  $0.50: 500 traded vs 2559 OI:  Earnings 3/28 After Close (est)  $2.86 Ref,2017-01-09 09:31:00-05:00,NYMX,positive
941701.0,Nymox Pharma Shares to Resume Trade at 9:50:43 a.m. EDT,2016-11-29 09:49:00-05:00,NYMX,positive
941702.0,UPDATE: Nymox Says Results Confirm That Patients Who Received Fexapotide as Initial Treatment for PBH Had Superior Efficacy Results as Early as 10 Days,2016-11-29 09:49:00-05:00,NYMX,positive
941703.0,"Nymox Pharma Reports Added Positive Results from Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response, First-Line Efficacy",2016-11-29 09:48:00-05:00,NYMX,positive
941704.0,Nymox Pharmaceutical Halted On Circuit Breaker,2016-11-29 09:47:00-05:00,NYMX,neutral
941705.0,"6-K from Nymox Pharma Shows Q3 EPS $(0.07) vs $(0.26) in Same Qtr. Last Year, Sales $51.98M vs $46.852M YoY",2016-11-15 14:01:00-05:00,NYMX,neutral
941706.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-11-07 07:11:00-05:00,NYMX,neutral
941707.0,"25 Stocks Which Rallied Four Days, Then Sold Off On Friday",2016-10-24 06:24:00-04:00,NYMX,neutral
941708.0,5 Stocks Which Rallied Three Days On Increasing Volume,2016-10-12 09:48:00-04:00,NYMX,neutral
941709.0,Mid-Afternoon Market Update: Dow Drops 250 Points; Biostar Pharmaceuticals Shares Spike Higher,2016-10-11 14:42:00-04:00,NYMX,positive
941710.0,8 Biggest Mid-Day Gainers For Tuesday,2016-10-11 12:28:00-04:00,NYMX,neutral
941711.0,Mid-Day Market Update: Rent-A-Center Drops On Disappointing Q3 Outlook; Nymox Shares Surge,2016-10-11 12:27:00-04:00,NYMX,negative
941712.0,Nymox Shares Up 32% At $4.36,2016-10-11 10:07:00-04:00,NYMX,positive
941713.0,Nymox Halted on CB,2016-10-11 10:01:00-04:00,NYMX,neutral
941714.0,Nymox Announces Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment [,2016-10-11 10:01:00-04:00,NYMX,positive
941715.0,Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment,2016-10-11 10:00:00-04:00,NYMX,positive
941716.0,10 Biggest Mid-Day Gainers For Tuesday,2016-09-13 12:50:00-04:00,NYMX,neutral
941717.0,"Adam Feuerstein @adamfeuerstein Tweet: $NYMX issues new PR this morning which just repeats the same misleading, erroneous talking points about failed fexapotide clinical trials.  10:34am · 29 Aug 2016",2016-08-29 10:35:00-04:00,NYMX,negative
941718.0,"Nymox Highlights Phase 3 LT U.S. Results For Prostate Enlargement, BZ NOTE: The Street's Adam Feuerstein Has Been Notably Bearish On The Stock Recently",2016-08-29 10:34:00-04:00,NYMX,positive
941719.0,"Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show Dramatic Decrease in Prostate Cancer, Major Reduction in Need For BPH Prostate Surgery",2016-08-29 10:33:00-04:00,NYMX,negative
941720.0,MoxReports ‏@MoxReports Tweet: $nymx. Yes...still short. It's a zero. But very expensive borrow.,2016-08-26 14:45:00-04:00,NYMX,neutral
941721.0,Adam Feuerstein @adamfeuerstein Tweet: Jabbing A Needle in the Overinflated $NYMX Prostate Drug Hype thestreet.com/story/13686959…,2016-08-26 14:31:00-04:00,NYMX,neutral
941722.0,12 Biggest Mid-Day Losers For Friday,2016-08-26 13:22:00-04:00,NYMX,negative
941723.0,18 Biggest Mid-Day Gainers For Thursday,2016-08-25 12:55:00-04:00,NYMX,neutral
941724.0,Mid-Day Market Update: Dollar General Falls Following Weak Results; AEP Industries Shares Spike Higher,2016-08-25 12:12:00-04:00,NYMX,negative
941725.0,Mid-Morning Market Update: Markets Edge Lower; Tiffany Profit Beats Estimates,2016-08-25 09:54:00-04:00,NYMX,positive
941726.0,"Adam Feuerstein @adamfeuerstein Tweet:$NYMX — For those new to the stock, a couple of older stories to warn you away.   thestreet.com/story/11003461…  thestreet.com/story/12775982…",2016-08-25 09:53:00-04:00,NYMX,negative
941727.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-08-25 08:26:00-04:00,NYMX,neutral
941728.0,"Adam Feuerstein @adamfeuerstein Tweet:  @RobertDurant7 There's really nothing to discuss w/r/t $NYMX. The ""drug"" is total zero w/ years of delays and failures behind it.",2016-08-25 07:27:00-04:00,NYMX,negative
941729.0,"After-Hours Gainers Aug. 24, 2016: GES Up 15%, TLYS 10.2%, BLDP 10%, WDAY 9.9%, NYMX 7.8%",2016-08-24 18:26:00-04:00,NYMX,neutral
941730.0,Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery By 82-95%,2016-08-24 12:20:00-04:00,NYMX,positive
941731.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-17 12:54:00-04:00,NYMX,neutral
941732.0,Nymox Pharma Reports Private Placements of $2.24M,2016-08-17 10:00:00-04:00,NYMX,neutral
941733.0,18 Biggest Mid-Day Gainers For Thursday,2016-08-11 12:50:00-04:00,NYMX,neutral
941734.0,"MoxReports ‏@MoxReports Tweet: $nymx  still short. thesis is unchanged.  pr is nonsense, as usual.",2016-08-11 10:49:00-04:00,NYMX,negative
941735.0,"UPDATE: Nymox Reports Major Progress in Evidence for Safety, Efficacy of Fexapotide for BPH, Low-Grade Prostate Cancer",2016-08-11 10:33:00-04:00,NYMX,positive
941736.0,Nymox Announces Prostate Drug Progress,2016-08-11 10:29:00-04:00,NYMX,positive
941737.0,Nymox Pharmaceutical Halted on CB at Low of $1.83,2016-08-10 12:36:00-04:00,NYMX,negative
941738.0,Nymox off Low @$2.89; May be Attributed to Negative Mox Report,2016-08-10 09:51:00-04:00,NYMX,negative
941739.0,Mid-Afternoon Market Update: Dow Turns Lower; Crude Oil Slides Over 2%,2016-06-22 14:31:00-04:00,NYMX,negative
941740.0,10 Biggest Mid-Day Gainers For Wednesday,2016-06-22 12:39:00-04:00,NYMX,neutral
941741.0,Shares of Nymox Pharma to Resume Trade at 10 a.m. EDT,2016-06-22 09:39:00-04:00,NYMX,positive
941742.0,Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer,2016-06-22 09:33:00-04:00,NYMX,negative
941743.0,Nymox Pharma Shares Halted News Pending,2016-06-22 09:15:00-04:00,NYMX,positive
941744.0,Nymox Says Study Successfully Met Its Pre-Determined Endpoints,2016-02-09 10:03:00-05:00,NYMX,positive
941745.0,"Nymox Reports Private Equity Placement Of $2.1M At $2/Share, Investments Made By Long-Time Shareholders",2016-02-04 11:17:00-05:00,NYMX,neutral
941746.0,Nymox Reports Added $2.1M in Equity Financing,2016-02-04 11:15:00-05:00,NYMX,neutral
941747.0,"Director Robinson Buys 20,000 Shares of Nymox Pharmaceutical $2.44/Share -Form 4",2016-01-13 11:03:00-05:00,NYMX,positive
941748.0,Nymox Pharma Reports Filing of Current Financial Statements,2015-12-31 16:47:00-05:00,NYMX,neutral
941749.0,"DJ Dir Robinson Buys 29,854 Shares of Nymox Pharmaceutical @$3.54/Share -Form 4",2015-12-24 11:06:00-05:00,NYMX,positive
941750.0,Mid-Afternoon Market Update: American Superconductor Gains On Strong Q3 Outlook; First Solar Shares Drop,2015-12-10 14:56:00-05:00,NYMX,positive
941751.0,UPDATE: Nymox Results Show Primary Endpoint Of Cross-Over Study Of Fexapotide Reached Statistical Significance,2015-10-29 10:33:00-04:00,NYMX,positive
941752.0,Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer,2015-10-29 10:31:00-04:00,NYMX,negative
941753.0,Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments,2015-10-08 11:00:00-04:00,NYMX,negative
941754.0,"Nymox Pharmaceutical Director Robinson Buys 100,000 Shares @$2.25/Share -Form 4",2015-09-08 17:17:00-04:00,NYMX,positive
941755.0,"UPDATE: Pedone Looking for Shares of Nymox to Close Over $3.31; If Shares Don't Close Over This Level, Warns Price 'subject to fail the break out and will get faded'",2015-08-12 15:37:00-04:00,NYMX,negative
941756.0,Zero Sum Trading's Roberto Pedone Highlighting Technical Levels in Shares of Nymox Pharma: Price 'failed at a clear resistance level of $3.25 after hitting an intraday high of $3.31',2015-08-12 15:36:00-04:00,NYMX,positive
941757.0,"Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More",2015-07-27 12:36:00-04:00,NYMX,negative
941758.0,Sophiris Mentioned as Play on Nymox,2015-07-27 10:15:00-04:00,NYMX,positive
941759.0,Nymox Pharmaceutical Halted on Circuit Breaker +127%,2015-07-27 10:12:00-04:00,NYMX,neutral
941760.0,Shares of Nymox Pharma Now Up Nearly 55%,2015-07-27 10:09:00-04:00,NYMX,positive
941761.0,Nymox Shares Rise 87% as Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint,2015-07-27 10:05:00-04:00,NYMX,positive
941762.0,Shares of Nymox Open for Trade Up 37.5%,2015-07-27 10:00:00-04:00,NYMX,positive
941763.0,Shares of Nymox Halted News Pending,2015-07-27 09:15:00-04:00,NYMX,positive
941764.0,F-3 Filing Shows Nymox Pharmaceuticals To Offer 12M Shares By Selling Shareholders,2015-07-14 17:08:00-04:00,NYMX,positive
941765.0,Nymox Pharma Reports $850K Financing at Prices of $1.25-$1.66,2015-06-16 12:13:00-04:00,NYMX,neutral
941766.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI,2015-05-13 04:45:00-04:00,NYMX,positive
941767.0,"Top Performing Industries For May 6, 2015",2015-05-06 10:57:00-04:00,NYMX,positive
941768.0,UPDATE: Nymox Shares Rise 56% on Positive Prostate Cancer Trial Results,2015-04-20 10:05:00-04:00,NYMX,positive
941769.0,Nymox Reports New Prostate Cancer Clinical Trial Results,2015-04-20 10:01:00-04:00,NYMX,negative
941770.0,These 5 Stocks Have More Than Doubled In 2015,2015-04-06 09:00:00-04:00,NYMX,neutral
941771.0,Shares of Nymox Pharma to Resume Trade at 10:30 a.m. EDT,2015-04-01 10:06:00-04:00,NYMX,positive
941772.0,Nymox Announces Phase 3 BPH Studies,2015-04-01 10:00:00-04:00,NYMX,neutral
941773.0,shares of Nymox Pharma Halted News Pending,2015-04-01 09:55:00-04:00,NYMX,positive
941774.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI,2015-01-22 04:20:00-05:00,NYMX,positive
941775.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-12-18 04:44:00-05:00,NYMX,positive
941776.0,"Nymox Pharmaceutical Corporation Reports Q3 EPS of $(0.02), Up 75% YOY; Revenue of $81.13K",2014-11-14 10:01:00-05:00,NYMX,neutral
941777.0,Stocks Hitting 52-Week Lows,2014-11-03 10:13:00-05:00,NYMX,negative
941778.0,Morning Market Losers ,2014-11-03 09:48:00-05:00,NYMX,negative
941779.0,Nymox Shares Fall 79% Premarket on Failed  NX-1207 Trial,2014-11-03 08:13:00-05:00,NYMX,negative
941780.0,Nymox Reports NX-1207 BPH Pivotal Phase 3 U.S. Studies Fail to Meet Primary Efficacy Endpoints ,2014-11-02 16:47:00-05:00,NYMX,negative
941781.0,"Nymox Announces Positive Prostate Cancer 8-Month Clinical Trial Results, Statistical Significance Reduced Compared to Controls",2014-09-10 09:31:00-04:00,NYMX,positive
941782.0,"Nymox Pharmaceutical Corporation Reports Q2 EPS of $(0.02), Up 75% YOY; Revenue of $97.88K, Down 88% YOY",2014-08-11 09:30:00-04:00,NYMX,neutral
941783.0,Nymox Announces Positive Efficacy in Phase III NX-1207,2014-07-22 09:30:00-04:00,NYMX,positive
941784.0,Nymox Announces Completion of Enrollment For Second BPH Study,2014-07-15 09:30:00-04:00,NYMX,neutral
941785.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-07-14 04:55:00-04:00,NYMX,positive
941786.0,"Nymox Pharma Offers Update on Nerve Sparing, Sexual Function Related to Men Treated with NX-1207",2014-06-17 10:03:00-04:00,NYMX,neutral
941787.0,Nymox Offers Positive New Safety Study Data for Phase 3 BPH Drug,2014-06-11 10:16:00-04:00,NYMX,positive
941788.0, Nymox Pharma Reports Targeted Treatment With NX-1207 at Either Dose Had No Significant Effect on Reported Sexual Function Score Post-Treatment,2014-05-21 09:55:00-04:00,NYMX,negative
941789.0,"Nymox Pharmaceutical Corporation Reports Q1 EPS of $(0.07), Up 13% YOY; Revenue of $78.0K vs $890.0K Est",2014-05-15 09:47:00-04:00,NYMX,neutral
941790.0,Nymox Reports Positive Results on NX-1207: Does Not Affect Testosterone Levels,2014-05-13 09:46:00-04:00,NYMX,positive
941791.0,Nymox Announces Completion of Second Phase 3 NX-1207 Trail for BPH,2014-05-08 10:31:00-04:00,NYMX,neutral
941792.0,Nymox Reports New Prostate Cancer Clinical Trial Results,2014-05-06 10:00:00-04:00,NYMX,negative
941793.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROE,2014-05-05 05:10:00-04:00,NYMX,positive
941794.0,Mid-Day Market Update: Twitter Drops On Earnings; Pepco Shares Gain,2014-04-30 13:18:00-04:00,NYMX,positive
941795.0,Shares of Nymox Sharply Lower by 5.5% After Reporting Top-Line Results from Phase 2 Study of NX03-0040,2014-04-30 11:03:00-04:00,NYMX,neutral
941796.0,UPDATE: Nymox Pharmaceutical Shares Resume Trading Down 7% Following Release of Prostate Cancer Study Showing Mixed Results,2014-04-30 10:06:00-04:00,NYMX,negative
941797.0,Shares of Nymox Pharma Halted News Pending,2014-04-30 09:25:00-04:00,NYMX,positive
941798.0,Nymox Reports Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH ,2013-11-11 11:46:00-05:00,NYMX,positive
941799.0,"Nymox Pharma Issues Results on NX02-0018 Phase Trial, Initial Blush Looks Positive",2013-08-22 10:19:00-04:00,NYMX,positive
941800.0,Afternoon Market Gainers ,2013-07-16 13:00:00-04:00,NYMX,neutral
941801.0,Nymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial ,2013-07-11 12:45:00-04:00,NYMX,positive
941802.0,Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation,2013-04-02 17:06:00-04:00,NYMX,negative
941803.0,UPDATE: Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program,2013-02-19 10:17:00-05:00,NYMX,positive
941804.0,Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program,2013-02-19 10:17:00-05:00,NYMX,positive
941805.0,Nymox Pharmaceutical Reports Q2 EPS $-0.05 vs $-0.06 Est,2012-08-14 10:05:00-04:00,NYMX,neutral
941806.0,Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug,2012-07-31 10:43:00-04:00,NYMX,positive
941807.0,Nymox Announces Completion of Enrollment for Phase 3 BPH Re-Injection Study  ,2012-07-11 10:00:00-04:00,NYMX,neutral
941808.0,Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 BPH NX02-0020 Repeat Injection U.S. Study ,2012-07-09 13:46:00-04:00,NYMX,positive
941809.0,Nymox Announces First Patient Enrollment for Phase 2 Prostate Cancer Clinical Trial ,2012-06-12 10:15:00-04:00,NYMX,negative
941810.0,Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 NX-1207 Trials for BPH ,2012-04-26 11:45:00-04:00,NYMX,positive
941811.0,Nymox Announces New Positive Long-Term Follow-Up Study Results for Subjects Treated With NX-1207 for BPH ,2012-03-26 10:00:00-04:00,NYMX,positive
941812.0,Recordati and Nymox Announce the Start of European Phase III Clinical Trial for NX-1207 ,2012-02-21 09:30:00-05:00,NYMX,neutral
941813.0,Nymox Announces Current Safety Monitoring Committee Results and Update for Phase 3 NX-1207 Trials ,2012-02-15 11:20:00-05:00,NYMX,positive
941814.0,Singular Research: 6th Annual Best of The Uncovereds Conference Preview,2011-10-20 11:31:00-04:00,NYMX,positive
941815.0,Nymox Pharmaceutical Announces New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19  ,2011-10-19 12:55:00-04:00,NYMX,positive
941816.0,New Peer-Reviewed Publication in Therapeutic Advances in Chronic Disease Features Nymox NX-1207 Drug for BPH  ,2011-09-26 10:08:00-04:00,NYMX,neutral
941817.0,August 16 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile  ,2011-08-17 10:16:00-04:00,NYMX,positive
941818.0,Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19  ,2011-08-16 12:15:00-04:00,NYMX,neutral
941819.0,"UPDATE: E. Coli Sympathy Stocks Include PURE Bioscience, Strategic Dianostics, Nymox Pharma, Life Technologies, and Food Technology Service",2011-06-06 08:22:00-04:00,NYMX,positive
941820.0,Nymox Pharmaceutical Announces New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting ,2011-05-17 14:31:00-04:00,NYMX,positive
941821.0,Safety Monitoring Committee Meeting Positive for Nymox Pivotal Phase 3 NX-1207 Trials  ,2011-05-04 10:45:00-04:00,NYMX,positive
941822.0,Nymox Announces Positive New Results in 7 Year Study of NX-1207 for Benign Prostatic Hyperplasia  ,2011-03-16 10:24:00-04:00,NYMX,positive
941823.0,Nymox Pharmaceutical Climbs 6.9% (NYMX),2010-12-31 15:49:00-05:00,NYMX,neutral
941824.0,Nymox Pharmaceutical Climbs 13.7% (NYMX),2010-12-23 14:43:00-05:00,NYMX,neutral
941825.0,"Morning Market Movers (ITMN, BASI, NYMX, MI)",2010-12-17 10:25:00-05:00,NYMX,neutral
941826.0,Nymox Up Huge After Recordati News (NYMX),2010-12-17 08:19:00-05:00,NYMX,positive
941827.0,Nymox Reports Third Quarter 2010 Financial Results ,2010-11-12 10:29:00-05:00,NYMX,neutral
941828.0,Under $5 Stocks at Risk of Defaulting,2010-08-05 13:18:00-04:00,NYMX,negative
941829.0,Nymox Pharmaceutical Corporation (NYMX) Announces Lead Drug in Development Shows Positive Results,2009-08-26 10:16:00-04:00,NYMX,positive
